Johnson & Johnson

06/28/2024 | Press release | Distributed by Public on 06/28/2024 08:05

CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic[...]